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Most mouse models of diabetes do not fully reproduce features
of human diabetic nephropathy, limiting their utility in
inferring mechanisms of human disease. Here we performed
detailed phenotypic and genetic characterization of leptin-
receptor (Lepr) deficient mice on the FVB/NJ background
(FVBdb/db), an obese model of type II diabetes, to determine
their suitability to model human diabetic nephropathy. These
mice have sustained hyperglycemia, significant albuminuria
and characteristic diabetic renal findings including mesangial
sclerosis and nodular glomerulosclerosis after 6 months of age.
In contrast, equally obese, hyperglycemic Lepr/Sur1 deficient
C57BL/6J (Sur1 has defective insulin secretion) mice have
minimal evidence of nephropathy. A genome-wide scan in 165
Lepr deficient backcross progeny derived from FVB/NJ and
C57BL/6J identified a major locus influencing nephropathy and
albuminuria on chromosome 8B1-C5 (Dbnph1 locus, peak lod
score 5.0). This locus was distinct from those contrasting
susceptibility to beta cell hypertrophy and HIV-nephropathy
between the same parental strains, indicating specificity to
diabetic kidney disease. Genome-wide expression profiling
showed that high and low risk Dbnph1 genotypes were
associated with significant enrichment for oxidative
phosphorylation and lipid clearance, respectively; molecular
pathways shared with human diabetic nephropathy. Hence,
we found that the FVBdb/db mouse recapitulates many clinical,
histopathological and molecular features of human diabetic
nephropathy. Identifying underlying susceptibility gene(s) and
downstream dysregulated pathways in these mice may provide
insight into the disease pathogenesis in humans.
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Diabetic nephropathy (DN) is the most common cause of
kidney failure worldwide.1 DN has characteristic histopatho-
logic features and is associated with dysregulation of a large
number of cellular and molecular pathways.2 Interindividual
variability in risk of DN and familial aggregation of the trait
have suggested significant genetic contribution to this disease.3–12
For example, only one-third of diabetics eventually develop
nephropathy, and up to one quarter of DN patients have a
relative with end-stage renal failure.3–12 Genetic and epidemio-
logic studies have also clearly shown that DN has complex
inheritance and the development of disease is determined by
the interplay of many risk alleles.3–12 Human linkage studies
have mapped susceptibility loci for DN to multiple segments
of the genome.3–9 Critically, these studies have indicated that
DN risk alleles are distinct from those conferring susceptibility
to diabetes or other forms of nephropathy3–12 and that discovery
of underlying genes would necessitate very large populations
concordant for diabetes duration but discordant for nephro-
pathy outcome. More recently, a genome-wide association study
(GWAS) has identified four suggestive susceptibility loci that
impart risk ratios of 1.3–1.5 on disease.12
As the result of additional GWAS results emerge in the
near future, relevant experimental models will be necessary to
characterize the role of implicated genes in disease pathogen-
esis. Genetic studies of murine models can provide a
powerful complement to human studies because they permit
rigorous control of genetic and environmental parameters,
and also provide the ability to readily access relevant tissues,
enabling careful dissection of disease-contributing pathways.
However, the best studied diabetes models, such as the
streptozotocin model or obese mice on the C57BL/B6
background (for example, leptin receptor-deficient mice)
only manifest mild proteinuria, minimal glomerulosclerosis
and no progression to renal failure, limiting inference to
human disease.13,14 It is not clear whether the absence of
classic DN in these models is attributable to genetic resistance
to diabetic renal complications, insufficient duration of
hyperglycemia, or a combination of both factors.13–22
The leptin receptor (Lepr) deficient mouse on the FVB/NJ
genetic background (FVBdb/db) is a validated model of
sustained type II diabetes.21–23 Lepr deficiency causes
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hyperphagia, insulin resistance, defective thermogenesis, and
infertility but the development of hyperglycemia is strain
dependent.16,21,22,24,25 The Lepr-deficient C57BL/6J mice
(B6db/db) only exhibit transient hyperglycemia,13,19 whereas
the Lepr-deficient C57BLKS/J mice develop severe hypergly-
cemia, which produces islet cell toxicity, rapidly leading to
severe metabolic derangements and early demise.16,25 In
contrast, the FVB/NJ beta cells are resistant to toxic effects of
hyperglycemia and expand sufficiently to secrete insulin and
permit survival.21,22 Consequently, the FVBdb/db mice exhibit
sustained diabetes for over 6 months, providing a powerful
model for examining the long-term complications of
hyperglycemia.23 Our previous genetic studies have shown
that the differential ability to expand beta cell mass between
the FVB/NJ and C57BL/6J strains is attributable to a major
gene on chromosome 5.22 Interestingly, these same strains
exhibit contrasting susceptibility to HIV-1-associated nephro-
pathy (HIVAN) and our mapping studies have recently shown
that these HIVAN susceptibility loci encode transregulators
of podocyte gene expression.24
Initial characterization of the FVBdb/db model had shown
development of glomerulosclerosis with several classic DN
features, as well as significantly increased renal lipid
accumulation.23 Here, we determined whether the divergent
DN phenotype between the B6db/db and FVBdb/db strains is
simply attributable to differences in duration of hyperglyce-
mia or reflected variation in genetic susceptibility to kidney
damage. As we had previously characterized determinants of
susceptibility to diabetes and HIVAN between the same
strains, this study was also able to distinguish whether the
murine DN susceptibility loci and downstream pathways are
the same or distinct from genetic factors mediating suscept-
ibility to diabetes or other forms of nephropathy.
RESULTS
Characterization of strains with contrasting genetic
susceptibility to DN
Both sexes of FVBdb/db mice show obesity, persistently
elevated blood glucose concentrations starting at weaning
(Table 1, Chua et al. and Luo et al.21,22). Consistent with
previous findings,23 a longitudinal study revealed the
development of massive albuminuria after 4–5 months of
age (Figure 1). By six months of age, the FVBdb/db had 10-fold
more albuminuria compared with non-diabetic counterparts.
This was accompanied by capillary basement membrane
thickening, diffuse mesangial sclerosis and nodular glomer-
ulosclerosis (Figure 2). In addition, the kidneys displayed
widespread tubulointerstitial disease, with microsystic tubu-
lar dilatation due to protein cast formation (Figure 2). The
sclerotic lesions involved 15–50% of glomeruli. In contrast
to other models of DN,13,14 there was no significant increase
in blood pressure or heart rate in obese FVBdb/db compared
with lean heterozygous counterparts (Figure 1). These data
demonstrate that the FVBdb/db strain is an excellent model for
studying the pathogenesis of DN.
In contrast to FVBdb/db the B6db/db mice only exhibit
transient hyperglycemia (B1–2 months) and minimal kidney
lesions (Table 1). This was confirmed in an independent
cohort of FVBdb/db and B6db/db mice studied at Albert
Einstein College of Medicine (Supplementary Table S1). To
distinguish whether this difference in severity of nephropathy
is attributable to variation in duration of hyperglycemia or
genetic susceptibility to kidney injury, we generated an
equally obese and hyperglycemic C57BL/6J model by
combining db and Sur1 null alleles in the C57BL/6J genetic
background (B6 Sur1/,db/db mice). The Sur1 gene encodes
one of the two subunits that compose the ATP sensitive K-
channel in the beta cell, and the loss of SUR1 causes a defect
in insulin secretion.25 The addition of Sur1 null alleles on the
B6db/db background resulted in sustained hyperglycemia and
glucose intolerance comparable with the FVBdb/db strain
(Table 1). However, detailed histological examination of both
B6db/db and B6 Sur1/,db/db kidneys at 6 months of age only
revealed glomerulomegaly and mild mesangial matrix
expansion without any evidence of glomerulosclerosis or
tubulointerstitial disease (Table 1, Figure 3). These data
demonstrated that the B6 genome confers protective alleles
that prevent the development of nephropathy. To determine
Table 1 | Characteristics of mouse cohort mice at 6 months of age
FVBdb/db B6db/db B6db/db Sur1/ (FVBxB6) F1 db/db Lean
Male
N 10 8 9 14 3
Weight (grams) 71.3±6.3** 61.4±9.3* 59.5±9.0* 70.8±6.1* 32.4±3.0
Glucose (mg/dl) 369±173* 191±159 327±141* 561±55** 95±33
Insulin (ng/ml) 47.0±26* 58.6±45 38.6±33 10.9±12 2.9±1.6
Histology scores 4.3±0.9# 0.5±0.5 0.8±0.7 0.8±0.8 0.1±0.4
Female
N 16 9 9 21 5
Weight (grams) 73.0±6.8*** 60.8±5.5*** 54.7±6.1*** 74.0±6.9 *** 32.4±3.0
Glucose (mg/dl) 239±107* 133±26 266±148* 411±81*** 115±15
Insulin (ng/ml) 485±154 *** 76.3±60* 24.8±33.1 60.9±31** 1.0±0.2
Histology scores 3.7±0.6# 0.3±0.5 0.5±0.5 0.5±0.5 0.2±0.4
Male and female mice were killed at 6 months of age. Data are presented as means and s.d. The group size refers to number of mice evaluated for weight, glucose and insulin.
The group size for histology scores are listed in Supplementary Table S1. Blood glucose was determined in the ad lib state. Lean mice are db+/ genotype on the B6 db+/ or
FVBdb+/ mice. *Po0.05, **Po0.001, ***Po0.0001 vs lean mice. #Po0.001 vs any other genotype group (two sided t-tests). The scores for subcomponents are shown in
supplemental data.
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Figure 1 |Characterization of blood pressure and proteinuria. (a) Tail cuff measurements show no differences in systolic blood pressure
and heart rate between FVB db/db and lean FVBdb/þ mice. (b) Serial SDS-PAGE of spot urine samples from one FVB db/db mouse at
three different ages. BSA standards are shown on the right panel. (c) Progressive increase in the proportion of mice showing albuminuria
41mg/ml, as measured by SDS-PAGE of spot urine samples compared with a dilution of BSA standard (N¼ 12–18 male and female mice
per age group). (d) Urine albumin/creatinine ratio at 28 and 52 weeks of age (*Po0.05 FVB db/db vs FVBdb/þ ).
Figure 2 |Histopathology of FVBdb/db kidneys. (a) Diffuse and global mesangial sclerosis affecting all glomeruli ( 20). (b) Glomerulus
with nodular mesangial sclerosis ( 60). (c) Hyaline accumulation in Bowman’s capsule forming a ‘capsular drop’ lesion ( 60). (d) Severe
mesangial sclerosis occluding glomerular capillary lumina in continuity with arteriosclerosis of the preglomerular arteriole ( 60).
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the likely mode of inheritance, we generated (FVBB6)db/db
F1 hybrids. Similar to B6 Sur1/,db/dbmice, F1 hybrids were
hyperglycemic but did not demonstrate any significant
evidence of renal disease at 6 months of age (Table 1). These
data indicated dominant inheritance of diabetes susceptibility
alleles, but recessive inheritance of nephropathy suscept-
ibility, suggesting that a backcross of the F1 hybrids to FVB
strain would localize DN susceptibility genes.
A major susceptibility locus for nephropathy maps to mouse
chromosome 8
To map nephropathy susceptibility loci, we generated 165 obese
[(FVBB6)F1 FVB]db/db backcross progeny. Animals were
killed at 6 months of age, and scored for multiple phenotypes
related to diabetic nephropathy (histopathology, albuminur-
ia, BUN). Virtually all of backcross progeny developed
sustained hyperglycemia by 6 weeks of age (95% with glucose
4250mg/dl). Despite uniform exposure to hyperglycemia,
61 of 165 mice (38%) had no evidence of renal involvement
based on normal renal histology and absence of proteinuria.
Similarly we observed a wide distribution of albumin
creatinine ratio (ACR) in the cross, consistent with increased
genetic variance (ACR range 5–4891 mg/mg). These data
showed segregation of nephropathy predisposing genes in
this cross and further suggested that these genes are distinct
from those contributing to diabetes susceptibility.
A genome-wide scan was performed with 103 informative
markers across the autosomes. A non-parametric analysis was
performed for the histology score, because this trait could not
be transformed to normality; both parametric (EM mapping)
and non-parametric analyses were used for albuminuria and
BUN. There was no linkage to the chromosome 5 locus that
mediates pancreatic beta-cell hypertrophy and insulinemia in
FVB, demonstrating that insulinemia is not a likely causal
Figure 3 |Comparison of histopathology between FVBdb/db (a–c) and B6db/db Sur1/ (d–f). There is diffuse and global mesangial sclerosis
in FVBdb/db mice (a,  40) but minimal mesangial sclerosis in B6db/dbSur1/ glomeruli (d,  40). Proteinaceous casts dilate the outer
medullary tubules in FVBdb/db mice (b,  60), but not B6db/db Sur1/ mice (e,  60). Electron micrograph of FVBdb/db glomerulus shows
thickened glomerular basement membranes and effaced foot processes (c). A representative capillary of B6db/dbSur1/ glomerular capillary
shows normally thin glomerular basement membrane with intact foot processes (f).
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factor for nephropathy in our model.22 Consistent with
uniform hyperglycemia in the backcross and the dominant
effect of the chr. 5 locus on persistent hyperglycemia,22 we
found no major loci for glucose levels in our cross. In
contrast, examination of renal phenotypes revealed signifi-
cant linkage of the global histology score and albuminuria to
chr 8 with lod scores of 4.2 and 2.9, respectively. To maximize
inheritance information and confirm linkage, we fine
mapped the region with seven additional markers. This
fine-mapping procedure confirmed our initial findings,
yielding non-parametric lod scores of 5.0 and 3.6 for the
global histology score and albuminuria (peak at 40 cM
between D8Mit178 and D8Mit248, Figure 4). This linkage
was robust to each component of histology scores, with
glomerulosclerosis and the tubular dilatation/casts scores
yielding lod scores of 4.5 and 3.3, respectively (Figure 5). In
parametric analysis, the ln transformed ACR also yielded a
lod score of 3.3 on chromosome 8. These phenotypes all
reach genome-wide significance by traditional criteria for a
backcross (that is, lod X3.3). Moreover, these traits
exceed empiric significance thresholds based on 10,000
permutations of phenotypes on genotype (genome-wide
P-valueo0.0001 for global histology score and P¼ 0.004 for
ACR, respectively). Remarkably, if global renal histology
score was treated as a binary trait, grouping as unaffected the
61 mice with no evidence of albuminuria and kidney injury
and classifying all others as affected, there was still significant
evidence of linkage to chromosome 8 with lod¼ 3.0 at
D8Mit248 (Figure 4b, e), suggesting a quasi-Mendelian effect
on phenotype. We have named this locus Dbnph1 (Diabetic
nephropathy 1). At the Dbnph1 locus, the FVB allele
significantly increased the risk of disease, conferring a
doubling of the global histology and 60% increase in
albuminuria traits (Figure 5). There were no other traits
showing linkage to the Dbnph1 locus. Although significantly
correlated with histology and albuminuria, BUN demon-
strated a suggestive signal on chromosome 6 (peak lod¼ 2.5
at rs3688920). Thus, the linkage to chromosome 8 remained
the only significant signal across the genome.
Genome-wide gene expression profiling reveals differentially
activated pathways in mice carrying Dbnph1 susceptibility
and resistance alleles
To gain insight into pathogenic pathways that are dysregu-
lated in the diabetic mice, we performed gene expression
profiling of whole kidney in 10 male obese backcross mice.
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Figure 4 | Linkage of diabetic nephropathy to chromosome 8 in backcross mice. Distribution of histology score as quantitative trait
(a) and binary trait (b, 1¼ no disease, 2 ¼ any disease), and Ln-transformed albumin/creatinine ratio (c). Below each histogram, the
genome-wide lod plots for these traits for non-parametric analysis of linkage (after fine-mapping with seven microsatellite markers on
chromosome 8) are shown (d–f). The x axis denotes genetic distance in centimorgans (cM), chromosomes are listed on the bottom.
The y axis shows the lod score. The dashed lines represent the genome-wide significance thresholds based on 10,000 permutations.
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We selected backcross mice without glomerulosclerosis that
harbored either FVB/FVB or FVB/B6 genotype across the
entire length of chromosome 8. Because of the large effect of
the Dbnph1 locus on nephropathy phenotypes, the mice with
the high risk FVB/FVB genotype on chromosome 8 had
significantly higher ACR compared with mice with the low
risk FVB/B6 genotype (215±132 vs 12±6, P¼ 0.009). This
design enabled comparison of expression profile in mice with
high and low likelihood of progression to overt DN, while
minimizing detection of ‘secondary’ gene expression changes
due to overt kidney injury. To detect dysregulated pathways,
we used gene set enrichment analysis (GSEA),26 a sensitive
analytic method for detecting coordinated enrichment for
genes belonging to known molecular pathways (gene sets).
Using GSEA, we interrogated 639 canonical pathways curated
by the Molecular Signature Database.26 GSEA showed that
mice with the FVB/FVB genotype on chr. 8 have significant
enrichment for oxidative phosphorylation (OXPHOS) path-
ways (FWER P-value¼ 0.009 based on 10,000 permutations,
Table 2), whereas mice with the protective FVB/B6 genotype
on chr. 8 displayed significant enrichment for complement
and coagulation pathways (FWER Po0.0001), statin/ABC
transporters and peroxisome proliferator-activated receptor
(PPAR) signaling (FWER Po0.0001), and several
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Figure 5 | Linkage of nephropathy subphenotypes to chromosome 8. (a) Lod plot demonstrating linkage of all nephropathy
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shows the lod –2 interval for the Dbnph1 locus. (b) Phenotypic values associated with FVB/FVB vs FVB/B6 genotype at the peak lod score
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Table 2 | Pathways enriched in backcross mice with contrasting genotypes at the Dbnph1 locus
Gene set name No of genes NES Nominal P-value FDR Q-value FWER P-value
Enriched in mice with FVB/FVB genotype
Hsa00190 oxidative phosphorylation 116 2.02 o0.0001 0.006 0.009
Oxidative phosphorylation 55 1.885 0.0003 0.02 0.05
Enriched in mice with B6/FVB genotype
Hsa04610 complement and coagulation cascades 62 2.55 o0.0001 o0.0001 o0.0001
Hsa00980 metabolism of xenobiotics by cytochrome p450 48 2.35 o0.0001 o0.0001 o0.0001
Hsa03320 PPAR signaling pathway 67 2.23 o0.0001 o0.0001 o0.0001
Tryptophan metabolism 49 2.22 o0.0001 o0.0001 o0.0001
Statin pathway PHARMGKB 16 2.15 o0.0001 o0.0001 o0.0001
Hsa00120 bile acid biosynthesis 35 2.13 o0.0001 o0.0001 0.0002
Intrinsic pathway 21 2.10 o0.0001 o0.0001 0.0004
Hsa00150 androgen and estrogen metabolism 28 2.1 o0.0001 o0.0001 0.0005
Blood clotting cascade 19 2.09 o0.0001 0.0001 0.001
Hsa00500 starch and sucrose metabolism 65 2.09 o0.0001 0.0004 0.002
Gamma hexachlorocyclohexane degradation 25 2.02 o0.0001 0.0004 0.004
Hsa00591 linoleic acid metabolism 28 2.01 o0.0001 0.0004 0.003
Hsa02010 ABC transporters general 41 1.99 o0.0001 0.0004 0.005
Hsa04640 hematopoietic cell lineage 74 1.97 o0.0001 0.001 0.02
Abbreviations: FDR, false discovery rate; FWER, family-wise error rate; NES, normalized enrichment score, a metric for gene set enrichment analysis (GSEA).
The name and the number of genes in each enriched gene set are indicated.
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overlapping amino acid synthetic/metabolic pathways
(FWER Po0.0001). Among these, the OXPHOS and PPAR
signaling pathways were particularly noteworthy because they
have been respectively implicated in initiation and ameliora-
tion of human DN.27–31 The leading edge subsets for both
pathways (that is, the subset of genes that accounted for most
of the enrichment score) included many canonical genes in
the OXPHOS (for example, cytochrome c oxidase and NADH
dehydrogenase subunits) and PPAR signaling (for example,
PPARg and PPARa). These findings were confirmed by
repeating GSEA with five independently curated gene sets
representing OXPHOS- and PPAR-signaling pathways
(Po0.001 for each, Supplementary Table S2). As the
components of these pathways are located on other
chromosomes, these changes can only be attributed to
transregulation by the chromosome 8 nephropathy suscept-
ibility alleles. Moreover, because we profiled mice before
development of glomerulosclerosis, these data suggest that
activation of OXPHOS and PPAR signaling characterize high
and low risk of progression to overt DN lesions.
Annotation and prioritization of positional candidates on
chromosome 8
The lod-2 interval for the chromosome 8 QTL spans440Mb
between D8Mit65 and D8Mit211 and contains over 545
positional candidates. To resolve this region further, we
performed haplotype comparisons between the FVB and B6
strains to identify segments that are non-identical by descent.
We identified 270 candidates with different haplotypes
between the two strains. We annotated these genes based
on three approaches (Supplementary Table S3). We first
searched for genes that are differentially expressed between
mice with the FVB/B6 and FVB/FVB genotypes at the
chromosome 8 locus, identifying 14 genes at a nominal
Po0.05 (that is, likely to harbor cis-eQTLs). We also
determined which positional candidate harbor potentially
pathogenic missense variants. This identified 144 missense
variants in 81 positional candidates; analysis with SIFT
predicted 9/144 missense SNPs to be damaging. Finally, we
examined, which positional candidates show the highest
correlation with leading edge subsets in the OXPHOS and
PPAR-signaling pathways. We further confirmed these
annotation results by measuring gene expression in an
expanded set of 20 backcross mice without glomerulo-
sclerosis for three positional candidates that had a cis-eQTLs
based on microarray data (Ndufa13, JunD and Ocel1). This
confirmed that the expression of these genes is regulated by
a cis-eQTL, validating the microarray results (Figure 6). We
next sequenced the promoter region, coding segments and 30
UTR of these three positional candidates. We identified all
SNPs annotated in NCBI and the Mouse Phenome Database,
but also uncovered several non-coding sequence variants that
were not annotated in databases (Supplementary Table S4),
consistent with incomplete polymorphism discovery
among inbred strains.32 The full annotated gene list is
presented in Supplementary Table S3, representing the initial
characterization of positional candidates, which can be
studied further to identify the underlying susceptibility
gene(s).
DISCUSSION
Most murine models of diabetes do not reproduce the full
features of human DN.13,16,17 Inadequate exposure to
hyperglycemia and genetic resistance likely contributes to
the lack of advanced DN lesions.13,14 In this study, we
describe the FVBdb/db mouse as a very useful tool for
dissecting genetic pathways underlying DN. The distinguish-
ing feature of this model is the resistance of beta cells to toxic
effects of hyperglycemia and continued increase in insulin
secretion from beta-cell mass expansion, which partially
compensates for mounting insulin resistance. This results in
sustained diabetes and reliable onset of DN with cardinal
histological features of disease after 6 months of age. By
generating hyperglycemic B6db/db Sur1/ and F1 hybrids with
comparable levels of hyperglycemia, we further showed that
the development of DN in FVBdb/db was not simply due to the
duration of diabetes but attributable to intrinsic genetic
vulnerability to this diabetic complication.
We identified a major locus on chromosome 8B1-C5
(Dbnph1) influencing the development of nephropathy in the
FVBdb/db strain. Remarkably, this locus was the only
significant signal across the genome and conferred a very
large effect, almost doubling the global histology score. The
linkage findings were robust to parametric and non-
parametric analytic methods and affected all major nephro-
pathy phenotypes. In addition, the Dbnph1 locus was also
distinct from loci influencing contrasting susceptibility to
beta-cell mass expansion (chr. 5) and the development of
HIVAN (chr. 4 and 13) between FVB and B6 strains.22,24
There was no evidence suggesting that the Dbnph1 locus
promotes the development of nephropathy by influencing
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Figure 6 |Genotypic differences in expression of selected
transcripts among mice with no evidence of
glomerulosclerosis. Jund, Ocel1, Ndufa13. y axis expression level
normalized to a wild-type B6 mouse. FF¼ FVB/FVB genotype
(n¼ 7) and FB¼ FVB/B6 genotype (N¼ 13) at the Dbnph1 locus
on chromosome 8. *Po0.05 by t-test.
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serum glucose levels: there were no correlations between
glucose levels and any renal histopathology or albuminuria
parameters; our previous study using the same parental
strains had demonstrated that variation in severity of diabetes
between FVB and B6 is attributable to a dominant locus on
chromosome 5 (ref. 24); consistent with the above finding and
the dominance of the chr 05 locus, all mice in our backcross
cohort were diabetic and linkage scans for serum glucose
levels did not reveal any loci influencing glucose levels; and
incorporation of glucose levels as a covariate in the linkage
analysis did not change linkage of nephropathy parameters to
chromosome 8. Taken together, these data demonstrates that
independent genetic factors influence insulinemia, DN and
HIVAN phenotypes between FVB and B6 strains, further
recapitulating the situation in humans.
Our previous studies had also shown that HIVAN
susceptibility alleles produce differential expression of many
podocyte genes, showing that HIVAN loci transregulate
podocyte gene expression.24 To gain insight into dysregulated
pathways, we followed up the current mapping experiments
by gene expression profiling in backcross mice with
nephropathy susceptibility or resistance alleles. We identified
several differentially expressed pathways that had been
previously implicated in human DN. In particular, the
activation of PPAR signaling in mice with the DN protective
alleles is consistent with recent studies showing that PPAR
agonists reduce proteinuria and kidney injury in humans and
Lepr mice.27–29 These data are also consistent with studies
implicating lipid accumulation in the pathogenesis of
nephropathy in FVBdb/db and other DN models, as well as
humans.23,33 In addition, the upregulation of OXPHOS
pathways in mice with the susceptibility alleles recapitulates a
recent study that identified upregulation of this pathway in
skin fibroblasts of patients with rapid progression of DN.30
Altogether, the finding of a locus that is specific for DN and is
enriched for genetic pathways previously implicated in
differential susceptibility to human DN provide compelling
evidence for the relevance of the FVBdb/db model and the
Dbnph1 locus to human disease.
Recent studies have shown that combining gene expres-
sion profiling with QTL analysis can stratify genes by
identification of cis expression QTLs.34 We therefore
performed an initial annotation of cis-eQTLs within the
Dbnph1 interval and found several positional candidates that
have been implicated in the pathogenesis of nephropathy. For
example, Jund, a component of the AP-1 complex, has been
implicated in preventing the wave of proliferative lesions
subsequent to nephron reduction surgery, through activation
of TGF-alpha.35 In addition, variation in Jund was recently
shown to mediate glomerular macrophage infiltration and
inflammation in experimental glomerulonephritis in mice.36
Ndufa13 (aka Grim19) is a mitochondrial complex I protein
that is important for cellular respiration and regulation of
apoptotic signaling through interactions with Stat3,37 a
transcription factor implicated in diabetic nephropathy.38
Finally, Ocel1, a gene of unknown function, was also notable
because it displayed the strongest cis-eQTL at the chromo-
some 8 locus, and expression was highly correlated with the
OXPHOS pathway. These data can be pursued by generation
of congenic strains that capture and isolate the linkage
interval, enabling refinement of the DN susceptibility gene(s)
and better detection of additional cis-eQTLs.
To date, the FVBdb/db has been independently studied by
investigators at four different sites (Columbia University,
Albert Einstein College of Medicine, University of Denver
and at Jackson laboratories for AMDCC).14,21–23 All four sites
have found significant evidence of alburminuria in this strain
after 6 months of age (410-fold increase compared to lean
counterparts after 6 months, satisfying a major AMDCC
criterion for DN). In addition, all sites, except for the
AMDCC study, also found histopathological evidence of
nephropathy, as described in this study. The reasons for
absence of histopathological lesions in the AMDCC study are
not clear, and may be due to variation in environment, diet
or microflora. However, the severity of albuminuria in the
FVBdb/db colony studied by AMDCC completely recapitulates
the findings in our study, suggesting that with a longer
follow-up period, histopathological lesions consistent with
our observations would have been observed. These data
highlight the complexity of mouse genetic studies of diabetic
complications, suggesting that variation in gene, environ-
ment and in particular, length of follow-up should be
considered in evaluation of models.
Genome scans among diabetic and non-diabetic human
populations have identified a number of loci influencing
albuminuria, glomerular filtration rate (GFR) or the risk of
renal failure.3–9 These studies have strongly suggested multi-
factorial determination of disease.3–9 Most recently, a GWAS
for DN has identified suggestive signals in the CPVL/CHN2,
FRMD3, CARS genes and several intergenic loci.12 Associa-
tion studies have also identified genes or loci underlying GFR
(UMOD, SHROOM3 and STC139 and non-diabetic kidney
failure (MYH9, Kopp et al. and Kau et al.10,11). Neither of
these genes map to mouse chromosome 8 nor showed
differential expression based on Dbnph1 genotype. However,
as we develop Dbnph1 congenic strains and more GWAS loci
become available, the Dbnph1 locus can be better clarified in
the context of human disease. In addition, it is likely that
future GWAS projects will uncover more signals encompass-
ing multiple genes or intergenic regions of unknown
function, necessitating follow-up studies in validated experi-
mental models. Thus the FVBdb/db model will likely prove
very relevant for identification of pathways leading to human
kidney failure, but also for functional characterization of loci
identified in human genetics studies.
RESEARCH DESIGN AND METHODS
Animal breeding and phenotypes
The FVBdb/db strain was produced by 410 generation of
backcrossing of the db allele from the C57BLKS/J to the
FVB/NJ strain. A genome-scan with 103 informative markers
in the 10th generation detected no C57BLKS/J-derived alleles,
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demonstrating successful introgression of the db allele into
the FVB/NJ genome. We obtained Sur1 knockout mice from
Drs Joe and Lydia Aguilar-Bryan (Baylor College of
Medicine) and backcrossed the Sur1 KO allele to C57BL/6J-
db mice for 410 generations. A mapping cohort was
produced by backcrossing FVBB6db/þ or FVBB6db3J/þ
F1 hybrids to FVBdb/þ mice and their obese progeny
phenotyped mice at 24 weeks of age. Both the db and db-3J
alleles encode loss of function mutations in the LEPR,
resulting in obesity and metabolic phenotypes that are
indistinguishable on the B6 background.40 Three primary
phenotypes related to renal disease were characterized: renal
histology, blood urea nitrogen (BUN), and proteinuria. Urine
ACR was quantitated by ELISA (Albuwell and creatinine
companion kits from Exocell, Philadelphia, PA, USA); ACR
values were Ln transformed to achieve a normal distribution
for linkage analysis and comparison between genotypes.
Urine samples from the various F1 hybrids were not available
because they were lost during an institutional move (SC).
Renal histology was scored independently by an investigator
(VDD) blinded to genetic background and other traits. We
adapted a semi-quantitative scoring system that we have
validated for four previous mouse mapping studies of
nephropathy. We performed a standard grading for mesangial
sclerosis and supplemented this with additional entries for
progression to more extensive glomerulosclerosis (segmental
or global) as a measure of glomerular chronicity. We also
included tubulointerstitial lesions that may accompany
proteinuria (such as casts) and tubular atrophy/interstitial
fibrosis (which are measures of progression to chronicity).
These additional parameters may be seen in mouse models of
diabetic nephropathy with potential to progress (such as the
Ove26 mouse) as well as human diabetic nephropathy. For
each animal, we counted 100 glomeruli and scored three
parameters: (1) the percent of glomeruli that exhibit any
degree of glomerulosclerosis; (2) the percent of glomeruli
that exhibit any degree of mesangial sclerosis; (3) the percent
of tubules exhibiting dilatation or casts using a semi-
quantitative scale: 0¼ no disease, 1¼ 1–25% of tissue
showing abnormalities, 2¼ 26–50%, 3¼450% of tissue
affected. As these values were highly correlated, we also
computed a global histological score as sum of three
histology injury parameters (range 0–9). Blood pressure was
measured using non-invasive tail cuff method; mice were
acclimated for 5 days before measurements. The protocol was
approved by the IACUC committee at the Columbia
University Medical Center and the Albert Einstein College
of Medicine.
Genotyping and analysis of linkage
The mapping cohort was genotyped using 103 informative
SNPs across mouse autosomes (Kbioscience, Hoddesdon
Herts, UK). The SNPs were interpolated on the Whitehead
Institute genetic map by correlating their physical position
with the nearest microsatellite marker on NCBI build 37.
Primary phenotypes analyzed were the global histology score,
BUN and urine albumin/creatinine ratio. Multipoint lod
scores were calculated using the R/QTL package.41 Because all
histology traits were skewed and could not be transformed to
a normal distribution, non-parametric analyses were
performed for these traits. However, both parametric
(expectation/maximization (EM) mapping method) and
non-parametric analyses were performed after Ln transfor-
mation for urine albumin/creatinine ratio and BUN (which
resulted in a normal distribution). Traditional thresholds for
significance in the backcross were used (lod score 43.3,
Lander and Kruglyak42). In addition, we conducted 10,000
permutations of phenotypes on genotype to determine the
empirical significance of linkage findings.
Microarray analysis
We performed microarray analysis with the Affymetrix ST 1.0
exon arrays (Santa Clara, CA, USA). Total kidney RNA was
extracted from 10 backcross mice with no glomerulosclerosis
or proteinuria and selected to have FVB/FVB or FVB/B6
genotypes across chromosome 8 (five of each genotype).
Sample preparation, labeling and hybridization will be
performed as per Affymetrix recommended protocol. Signal
intensities were normalized using the GCRMA method. Gene
Set Enrichment analysis was performed as implemented in
the Gene Pattern (Broad Institute, Subramanian26). For this
analysis, we utilized 639 canonical pathways curated by the
Molecular Signature Database (http://www.broad.mit.edu/
gsea/msigdb/index.jsp). To detect empiric significance of
enrichment results, we performed 10,000 permutation of
gene labels in the arrays. P-values were corrected for multiple
testing based on the familywise error rate (FWER), with FWER
Po0.05 considered significant evidence of enrichment.
Bioinformatics
Phenotype comparisons between inbred mice were con-
ducted using 2-sided t-tests assuming unequal variance.
In silico analysis of haplotype on chromosome 8 was
performed by downloading all SNPs that were polymorphic
between FVB and B6 and that were located within the
chromosome 8 lod –2 interval (Mouse Phenome Database).
These SNPs were cross-referenced with the NCBI build 37 to
identify positional candidates with differing haplotypes,
yielding a list of 14,633 SNPs located within 270 genes. This
SNP list was further filtered to identify missense sequence
variants (144 identified). All missense variants were analyzed
with SIFT43 to predict potentially pathogenic substitutions.
To detect cis-eQTLs on chromosome 8, compared microarray
expression values of positional candidates in backcross mice
based on genotypes on chromosome 8, using a two-sided t-test.
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